Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022Business Wire • 08/04/22
Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia TreatmentNewsfile Corp • 07/26/22
Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b ResultsNewsfile Corp • 07/19/22
Virios Therapeutics' Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid FibromyalgiaBusiness Wire • 06/01/22
Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/13/22
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 05/12/22
Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022Business Wire • 05/05/22
Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for FibromyalgiaBusiness Wire • 04/28/22
Virios Therapeutics' (VIRI) CEO Greg Duncan on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/17/22
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 03/17/22
Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022Business Wire • 03/10/22
Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022Business Wire • 03/08/22
Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVIDBusiness Wire • 02/28/22
Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect ConferenceBusiness Wire • 01/04/22
Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for FibromyalgiaBusiness Wire • 12/01/21
Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/11/21
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 11/11/21
Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021Business Wire • 11/04/21
Virios Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/02/21
Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video InterviewBusiness Wire • 08/16/21
Virios Therapeutics' (VIRI) CEO Greg Duncan on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 08/12/21